Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | WSD0922 |
Synonyms | |
Therapy Description |
WSD0922 is an EGFR inhibitor with blood brain barrier penetration activity, which may lead to anti-tumor activity in EGFR mutant CNS tumor and brain metastasis (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1326). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
WSD0922 | WSD0922-FU | EGFR Inhibitor (Pan) 62 | WSD0922 is an EGFR inhibitor with blood brain barrier penetration activity, which may lead to anti-tumor activity in EGFR mutant CNS tumor and brain metastasis (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1326). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04197934 | Phase I | WSD0922 | WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases | Recruiting | USA | 0 |